An interventional study of PCI revascularization strategy based on combined FFR and OCT assessment and PCI revascularization strategy based FFR assessment in Multivessel Coronary Artery Disease, Ischemia and Vulnerable Plaque, sponsored by Diagram B.V.. Active, not recruiting at 49 sites in 18 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Diagram B.V. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Ischemia with a site in Spain — 5 open to participants now, 8 under way, 1 of them phase 3. Ischemia · Spain.
Among the 27 studies in Ischemia with a site in Spain, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 with no phase, and was the 19th registered.
545 studies on the registry are indexed under Ischemia; 71 are open to participants now.
Browse Ischemia studies →5 of the 27 studies in Ischemia with a site in Spain are open now. Recruiting first, the newest first:
Eva Rumiz González · Sites in Spain
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Spain, Italy
Ages 18+
National University of Ireland, Galway, Ireland · Sites in Spain, Belgium, Ireland and 2 more countries
Ages 18+
DiaMedica Therapeutics Inc · Sites in Spain, United States, Belgium and 7 more countries
Ages 18–90
iVascular S.L.U. · Sites in Spain, France
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 3 · Phase 4 3
First in 1998; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,223 is above the median of 74 across 356 interventional studies indexed under Ischemia.
Median enrollment 181 across the 16 interventional studies, 200 across the 11 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 27 have an industry lead sponsor. The 10 most frequent:
Diagram B.V. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Diagram B.V. has 1 study filed under Ischemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Ischemia with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07571954iVascular S.L.U.Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Ischemia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The COMBINE-INTERVENE Trial will investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation.
The published COMBINE trial shows that patients carrying an OCT-detected thin-cap atheroma have a fivefold higher rate of the primary endpoint compared to patients without vulnerable lesion morphology, despite absence of ischemia. The most important finding of this trial is that not ischemia, but underlying lesion morphology could be the most important factor that predicts future adverse events. Together with the recently published ISCHEMIA trial, where ischemia guided revascularization failed to improve clinical outcomes compared to medical treatment, the COMBINE trial leads to a new way of thinking in interventional cardiology and also opens the door for new treatment strategies where a combined ischemic and morphologic assessment could lead to better clinical outcomes.
The COMBINE-INTERVENE Trial will investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation. The COMBINE-INTERVENE Trial is the first in line trial that will test focal percutaneous stenting for vulnerable plaque lesions independently from ischemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Angiographic criteria target lesion* (all criteria I-IV should be applicable):
I. DS ≥ 50% on visual estimation II. de novo lesion located in native (non-grafted) vessel III. lesion reference diameter of ≥ 2.0 mm IV. Thrombolysis In Myocardial Infarction (TIMI) 3 flow in all vessels (with exclusion of culprit lesions if MI at presentation)
*Target lesions are either culprit MI lesions or lesions where FFR will be performed. Patients are eligible if they have ≥ 2 target lesions or one culprit and ≥ 1 target lesion.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MVD \> 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment
Procedure: PCI revascularization strategy based on combined FFR and OCT assessment
MVD \> 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)
Procedure: PCI revascularization strategy based FFR assessment
PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with \> 70 % AS or MLA \< 2.5 mm2.
PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
Cardiac death, any MI or any clinically driven revascularization at 24 months between FFR&OCT guided revascularization versus FFR-guided revascularization
Cardiac death, any MI or any clinically driven revascularization at 24 months between FFR\&OCT guided revascularization versus FFR-guided revascularization
Time frame: 24 months
Cardiac death, any MI or any clinical-driven revascularization at 24 months excluding TLR events occurring from medically treated lesions with a FFR between 0.76-0.80 in the experimental arm
Cardiac death, any MI or any clinical-driven revascularization at 24 months excluding TLR events occurring from medically treated lesions with a FFR between 0.76-0.80 in the experimental arm
Time frame: 24 months
Cardiac death, any spontaneous MI or any clinically-driven revascularization at 24 months
Cardiac death, any spontaneous MI or any clinically-driven revascularization at 24 months
Time frame: 24 months
Cardiac death, any spontaneous MI or any clinically driven revascularization at 24 months
Cardiac death, any spontaneous MI or any clinically driven revascularization at 24 months
Time frame: 24 months
Analysis of corelab-approved primary endpoints, as per protocol analysis
Analysis of corelab-approved primary endpoints, as per protocol analysis
Time frame: 24 months
Plan to share: No
Started Mar 2022 (actual). Primary completion is estimated for Sep 2026, 54 months after the start.
Of 72 non-industry interventional studies with no phase under Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 54 months is above that.
Counting every sponsor, half of 83 studies reached it within 31 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diagram B.V.